No Data
No Data
Express News | Dyne Therapeutics Announces New Clinical Data From Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
Chardan Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics
Small U.S. Stocks Decrease; Dyne Therapeutics Takes Biggest Hit
Dyne Therapeutics Analyst Ratings
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy